Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Healthcare professionals (HCPs) play a crucial role in the adoption of artificial intelligence (AI) in the pharmaceutical industry. Learn how HCPs view the potential of AI and its impact on ...

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the field, biologics have ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson urged a US appeals court to revive lawsuits over Medicare drug pricing negotiations.

Discussions about the impact of AI have gained prominence this year. Business leaders have taken note, with a recent Accenture report finding that 98% of global executives agree that AI will play ...

Executing an effective commercial success strategy requires extensive planning and implementation within pharmaceutical companies that spans teams, functions, and geographies. Together, these ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Belgian biotech Galapagos has had a change of heart – and a change of ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. The complaint filed in a Seattle court alleges that Genmab ...

GSK has teamed up with two research organisations in the UK to explore a possible link between its shingles vaccine, Shingrix, and a reduced risk of dementia.

This year’s Veeva R&D and Quality Summit saw full-house attendance at the Marriott Auditorium Hotel in Madrid. The summit, brought together 1,200 industry leaders to explore how to enable faster ...

Changing Faces announces new board appointments for Ascend, iOnctura, Pfizer, CAMP4 Therapeutics, and HUTCHMED in March 2025. Stay updated on the latest developments in the pharmaceutical industry.

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.